Effect of Montelukast on Time-Course of Exhaled Nitric Oxide in Asthma: Influence of LTC4 Synthase A-444C Polymorphism

Pediatric Pulmonology

Volumn 36, Issue 5, 2003, Pages 413-420

  Whelan, Glenn J ^a,c   Blake, Kathryn ^a   Kissoon, Niranjan ^b   Duckworth, Laurie J ^a   Wang, Jainwei ^a   Sylvester, James E ^a   Lima, John J ^a,b  

^a NEMOURS CHILDREN S CLINIC   (United States)

^b UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Asthma; Exhaled nitric oxide; Montelukast; Polymorphism

Indexed keywords

EXHALED NITRIC OXIDE; LEUKOTRIENE; MONTELUKAST; NITRIC OXIDE; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOTRIENE C4 SYNTHASE GENE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPIROMETRY; STATISTICAL ANALYSIS;

ACETATES; ADOLESCENT; ANTI-ASTHMATIC AGENTS; ASTHMA; BREATH TESTS; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; NITRIC OXIDE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; QUINOLINES; SPIROMETRY; TIME FACTORS;

EID: 0142031051     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.10385     Document Type: Article

References (47)

1. Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis 1987;136:985-998.
2. Leff AR. Role of leukotrienes in bronchial hyperresponsiveness and cellular responses in airways. Am J Respir Crit Care Med 2000;161:125-132.
3. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645-655.
4. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy [Suppl] 2001;56:7-11.
5. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999;22:168-170.
6. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, et al. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1995;73:191-201.
7. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998;279:1181-1186.
8. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999;130:487-495.
9. Kissoon N, Duckworth L, Blake K, Murphy S, Silkoff PE. Exhaled nitric oxide measurements in childhood asthma: techniques and interpretation [in process citation]. Pediatr Pulmonol 1999;28:282-296.
10. Barnes PJ, Kharitonov SA. Exhaled nitric oxide: a new lung function test [editorial]. Thorax 1996;51:233-237.
11. Gustafsson LE. Exhaled nitric oxide as a marker in asthma. Eur Respir J [Suppl] 1998;26:49-52.
12. Sanders SP. Nitric oxide in asthma. Pathogenic, therapeutic, or diagnostic? Am J Respir Cell Mol Biol 1999;21:147-149.
13. Baraldi E, Azzolin NM, Zanconato S, Dario C, Zacchello F. Corticosteroids decrease exhaled nitric oxide in children with acute asthma. J Pediatr 1997;131:381-385.
14. Bratton DL, Lanz MJ, Miyazawa N, White CW, Silkoff PE. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study. Pediatr Pulmonol 1999;28:402-407.
15. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999;160:1227-1231.
16. Lanz MJ, Leung DY, White CW. Comparison of exhaled nitric oxide to spirometry during emergency treatment of asthma exacerbations with glucocorticoids in children. Ann Allergy Asthma Immunol 1999;82:161-164.
17. Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, Zamel N. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest 2001;119:1322-1328.
18. Nicosia S, Capra V, Rovati GE. Leukotrienes as mediators of asthma. Pulm Pharmacol Ther 2001;14:3-19.
19. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-697.
20. Kharitonov SA, Yates DH, Chung KF, Barnes PJ. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Eur Respir J 1996;9:196-201.
21. Yates DH, Kharitonov SA, Robbins RA, Thomas PS, Barnes PJ. Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. Am J Respir Crit Care Med 1995;152:892-896.
22. van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999;54:403-408.
23. American Thoracic Society. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children - 1999. Am J Respir Crit Care Med 1999;160:2104-2117.
24. Silkoff PE, McClean PA, Slutsky AS, Furlott HG, Hoffstein E, Wakita S, et al. Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am J Respir Crit Care Med 1997;155:260-267.
25. Deykin A, Halpern O, Massaro AF, Drazen JM, Israel E. Expired nitric oxide after bronchoprovocation and repeated spirometry in patients with asthma. Am J Respir Crit Care Med 1998;157:769-775.
26. Wechsler ME, Grasemann H, Deykin A, Silverman EK, Yandava CN, Israel E, et al. Exhaled nitric oxide in patients with asthma: association with NOS1 genotype. Am J Respir Crit Care Med 2000;162:2043-2047.
27. Grasemann H, Knauer N, Buscher R, Hubner K, Drazen JM, Ratjen F. Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am J Respir Crit Care Med 2000;162:2172-2176.
28. Mattes J, van's Gravesande KS, Moeller C, Moseler M, Brandis M, Kuehr J. Circadian variation of exhaled nitric oxide and urinary eosinophil protein X in asthmatic and healthy children. Pediatr Res 2002;51:190-194.
29. Lima JJ, Kissoon N, Murphy SP, Duckworth L. Ultradian rhythm of exhaled nitric oxide in children. Am J Respir Crit Care Med 2000;161:802 [abstract].
30. ten Hacken NH, van der Mark TW, Koeter GH, Postma DS. Exhaled nitric oxide is higher both at day and night in subjects with nocturnal asthma. Am J Respir Crit Care Med 1998;158:902-907.
31. Lanz MJ, Eisenlohr C, Llabre MM, Toledo Y, Lanz MA. The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast. Ann Allergy Asthma Immunol 2001;87:283-288.
32. Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol 2002;109:68-74.
33. Wilson AM, Orr LC, Sims EJ, Dempsey OJ, Lipworth BJ. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000;162:1297-1301.
34. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001;31:616-624.
35. Lipworth BJ, Dempsey OJ, Aziz I, Wilson AM. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype. Am J Med 2000;109:114-121.
36. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001;119:1021-1026.
37. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000;23:290-296.
38. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax [Suppl] 2000;55:28-31.
39. Kissoon N, Duckworth LJ, Blake KV, Murphy SP, Taylor CL, DeNicola LR, et al. Exhaled nitric oxide concentrations: online versus offline values in healthy children. Pediatr Pulmonol 2002;33:283-292.
40. Lum A, Le Marchand L. A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomarkers Prev 1998;7:719-724.
41. Marks RG. Designing a research project: the basics of biomedical research methodology. Belmont: Wadworth, Inc.; 1982.
42. Remington RD, Schork MA. Statistics with appliations to the biological and health sciences. 8 ed. Englewood Cliffs: Prentice-Hall; 1970.
43. Silkoff PE, Wakita S, Chatkin J, Ansarin K, Guitierrez C, Caramori M, McClean P, Slutsky AS, Zamel N, Chapman KR. Exhaled nitric oxide after beta2-agonists inhalation and spirometry in asthma. Am J Respir Crit Care Med 1999;159:940-944.
44. Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T, et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002;12:565-570.
45. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001;11:175-184.
46. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997;99:1130-1137.
47. Witte JS, Palmer LJ, O'Connor RD, Hopkins PJ, Hall JM. Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. Eur J Hum Genet 2002;10:82-85.